Pneumonia is one of the most common infectious diseases encountered worldwide. The major pathogen of community-acquired pneumonia (CAP) continues to be S. pneumoniae. In the hospital setting, S. aureus and Gram-negative bacteria are more commonly encountered and are frequently drug resistant. Delafloxacin is a novel fluoroquinolone antibiotic in development for the treatment of respiratory tract infections. It has a broad spectrum of activity that includes drug-resistant S. aureus, S. pneumoniae, and Klebsiella pneumoniae. The lowest MICs were observed for S. aureus (range, 0.004 to 0.008 mg/liter). The in vitro potency against S. pneumoniae and K. pneumoniae strains was more varied (range, 0.016 to 0.125 mg/liter and 0.06 to 1 mg/liter, respectively). As for pharmacokinetics, exposure to delafloxacin increased in a dose-dependent manner across the dose range. Cmax concentrations ranged from 2 to 71 mg/liter. AUC0–∞ values ranged from 2.8 to 152 mg · h/liter and were linear across the 2.5- to 160-mg dosing range (R2 of 0.99). The elimination half-life ranged from 0.7 to 1 h[3].
搜索
